4//SEC Filing
Venrock Healthcare Capital Partners III, L.P. 4
Accession 0001415889-25-002809
CIK 0001348911other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 7:42 PM ET
Size
21.5 KB
Accession
0001415889-25-002809
Insider Transaction Report
Form 4
Koh Bong Y
10% Owner
Transactions
- Purchase
Common Stock
2025-01-30$8.76/sh+43,707$382,873→ 4,986,480 total(indirect: By Funds) - Purchase
Common Stock
2025-01-31$8.89/sh+11,754$104,493→ 4,998,234 total(indirect: By Funds) - Purchase
Common Stock
2025-02-03$9.22/sh+14,562$134,262→ 5,012,796 total(indirect: By Funds)
Shah Nimish P
10% Owner
Transactions
- Purchase
Common Stock
2025-01-30$8.76/sh+43,707$382,873→ 4,986,480 total(indirect: By Funds) - Purchase
Common Stock
2025-01-31$8.89/sh+11,754$104,493→ 4,998,234 total(indirect: By Funds) - Purchase
Common Stock
2025-02-03$9.22/sh+14,562$134,262→ 5,012,796 total(indirect: By Funds)
VHCP Management III, LLC
10% Owner
Transactions
- Purchase
Common Stock
2025-01-30$8.76/sh+43,707$382,873→ 4,986,480 total(indirect: By Funds) - Purchase
Common Stock
2025-02-03$9.22/sh+14,562$134,262→ 5,012,796 total(indirect: By Funds) - Purchase
Common Stock
2025-01-31$8.89/sh+11,754$104,493→ 4,998,234 total(indirect: By Funds)
Transactions
- Purchase
Common Stock
2025-01-30$8.76/sh+43,707$382,873→ 4,986,480 total(indirect: By Funds) - Purchase
Common Stock
2025-02-03$9.22/sh+14,562$134,262→ 5,012,796 total(indirect: By Funds) - Purchase
Common Stock
2025-01-31$8.89/sh+11,754$104,493→ 4,998,234 total(indirect: By Funds)
VHCP Management EG, LLC
10% Owner
Transactions
- Purchase
Common Stock
2025-02-03$9.22/sh+14,562$134,262→ 5,012,796 total(indirect: By Funds) - Purchase
Common Stock
2025-01-31$8.89/sh+11,754$104,493→ 4,998,234 total(indirect: By Funds) - Purchase
Common Stock
2025-01-30$8.76/sh+43,707$382,873→ 4,986,480 total(indirect: By Funds)
Transactions
- Purchase
Common Stock
2025-01-31$8.89/sh+11,754$104,493→ 4,998,234 total(indirect: By Funds) - Purchase
Common Stock
2025-01-30$8.76/sh+43,707$382,873→ 4,986,480 total(indirect: By Funds) - Purchase
Common Stock
2025-02-03$9.22/sh+14,562$134,262→ 5,012,796 total(indirect: By Funds)
VHCP Co-Investment Holdings III, LLC
10% Owner
Transactions
- Purchase
Common Stock
2025-01-30$8.76/sh+43,707$382,873→ 4,986,480 total(indirect: By Funds) - Purchase
Common Stock
2025-02-03$9.22/sh+14,562$134,262→ 5,012,796 total(indirect: By Funds) - Purchase
Common Stock
2025-01-31$8.89/sh+11,754$104,493→ 4,998,234 total(indirect: By Funds)
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $8.74 to $8.91 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
- [F2]Consists of (i) 1,087,005 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 108,736 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,790,739 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
- [F3]VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $8.70 to $9.09 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
- [F5]Consists of (i) 1,089,036 shares held by VHCP3; (ii) 108,939 shares held by VHCP Co-3; and (iii) 3,800,259 shares held by VHCP EG.
- [F6]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.08 to $9.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
- [F7]Consists of (i) 1,091,552 shares held by VHCP3; (ii) 109,191 shares held by VHCP Co-3; and (iii) 3,812,053 shares held by VHCP EG.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001738048
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 7:42 PM ET
- Size
- 21.5 KB